Im­muno­Gen's lead armed an­ti­body fal­ters in key ovar­i­an can­cer test as a monother­a­py — shares crash

Im­muno­Gen’s lead armed an­ti­body — mirve­tux­imab so­rav­tan­sine — has failed a late-stage study as a monother­a­py in third line plat­inum-re­sis­tant ovar­i­an can­cer pa­tients, a miss that could de­rail stud­ies test­ing the drug as part of a com­bo.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER